Prospective Study
Copyright ©The Author(s) 2024.
World J Gastrointest Endosc. May 16, 2024; 16(5): 259-272
Published online May 16, 2024. doi: 10.4253/wjge.v16.i5.259
Table 4 Hazard ratio and 95%CI of clinical therapeutic outcomes (per-protocol population)
Therapeutic effect
HR (95%CI)
Multivariable adjusted HR (95%CI)1
Endoscopic characteristics improved
        Conventional group1.001.00
        Experimental group2.307 (1.202, 4.426)a2.545 (1.282, 5.052)b
Endoscopic characteristics deteriorate
        Conventional group1.001.00
        Experimental group0.793 (0.306, 2.055)0.979 (0.923, 1.037)
Biopsy pathology improved
        Conventional group1.001.00
        Experimental group3.320 (1.295, 8.507)a3.186 (1.179, 8.605)a
Biopsy pathology deteriorate
        Conventional group1.001.00
        Experimental group0.795 (0.259, 2.440)0.969 (0.896, 1.048)
HGIN or early cancer
        Conventional group1.001.00
        Experimental group0.382 (0.079, 1.846)0.750 (0.140, 4.015)